Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myocardial Fibrosis
- Molecular classification
- Extracellular Matrix Remodeling, Tissue Pathology
01
Overview
Myocardial fibrosis is characterized by the excessive accumulation of collagenous scar tissue within the myocardium, leading to increased ventricular stiffness, reduced contractility, and increased risk of arrhythmias and heart failure. It is a consequence of various cardiac insults including ischemia, pressure/volume overload, genetic disorders, and inflammation. While not a direct 'target' in the traditional sense, it represents a pathological process that can be influenced by therapies aimed at managing underlying conditions and potentially by emerging antifibrotic drugs.
- Other names
- Cardiac FibrosisHeart FibrosisMyocardial Scarring
02
Mechanism of action
Indirectly targeted through management of underlying conditions (e.g., hypertension, ischemia); direct antifibrotic therapies targeting TGF-β signaling are under investigation.
03
Biological functions
Extracellular matrix depositionTissue repairWound healingCardiac remodeling
04
Disease associations
Heart FailureArrhythmiasCardiomyopathyMyocardial InfarctionHypertensionAortic StenosisValvular Heart DiseaseMyocarditisGenetic Disorders affecting the heart
05
Safety considerations
Off-target effects of antifibrotic therapiesPotential for excessive fibrosis inhibition leading to tissue fragilityDifficulty in selective targeting of cardiac fibrosis without affecting other organsReversibility of fibrosis: The extent to which fibrosis can be reversed is limited.
06
Interacting drugs
ACE inhibitors
4 more in the full profile.
07
Biomarkers
Late Gadolinium Enhancement (LGE) on Cardiac MRIT1 mapping on Cardiac MRIExtracellular Volume Fraction (ECV) on Cardiac MRIFibroblast Activation Protein (FAP) expressionCirculating collagen fragments (research)TGF-β levels (research)
Beyond the preview
Go deeper on Myocardial Fibrosis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myocardial Fibrosis.